BTIG analyst Marie Thibault lowered the firm’s price target on Outset Medical (OM) to $15 from $17 and keeps a Buy rating on the shares. With stability in the company’s salesforce, a new product on the way, a broad and growing deal pipeline, strong recurring revenue, and improving margins, this was a solid quarter for rebuilding credibility, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical: Improving Visibility, Stronger Margins, and Next-Gen Tablo Support Buy Rating and $15 Target
- Outset Medical: Stabilizing Execution, Improving Margins, and Balanced 2026 Outlook Support Buy Rating Despite Lower Target
- Outset Medical reports Q4 EPS ($1.09), consensus (68c)
- Outset Medical sees FY26 revenue $125M-$130M, consensus $127.64M
- OM Earnings Report this Week: Is It a Buy, Ahead of Earnings?